Dr Brian Tse

BMedSc(Hon), DipInnovMan, PhD (all UNSW)

Senior Preclinical Imaging Scientist


Preclinical Imaging: Ultrasound and Photoacoustics, Positron Emission Tomography and Computed Tomography (PET-CT), Optical Imaging (bioluminescence & fluorescence), X-Ray, Nuclear Magnetic Resonance (NMR)

About me

Dr Tse is Senior Scientist of the TRI Preclinical Imaging Facility. He provides expertise to researchers on in vivo imaging in a collaborative manner, including image acquisition, data analysis, experimental design, project development, and supports grant and ethics applications.

He currently manages seven high-end preclinical imaging instrumentations; 1) Molecubes Beta and X cubes (microPET-CT and microCT), 2) Fujifilm Visualonics Vevo 2100 LAZR (high-frequency ultrasound and photoacoustics), 3) Perkin Elmer IVIS Spectrum (optical imaging), 4) Bruker Minispec LF50H (nuclear magnetic resonance; NMR), 5) Bruker Skyscan 1272 (ultra-high resolution microCT), 6) Faxitron Ultrafocus 100 (planar X ray), and 7) Perkin Elmer Wizard 2480 (gamma counting). His facility also supports preclinical radionuclide therapy studies eg lutetium177 (beta emitter) and actinium225 (alpha emitter).

Dr Tse obtained his PhD from the UNSW in 2011 in the field of cancer immunotherapy, where he also gained expertise in cutting-edge imaging modalities (optical imaging, ultrasound and microCT). He then undertook a two-year post-doctoral position at the Lowy Cancer Research Centre in Sydney before moving to Brisbane in 2012 to join QUT to work on several projects including prostate cancer imaging, and elucidating the molecular drivers of disease progression. He also has a Diploma In Innovation Management degree (UNSW).

Dr Tse has received funding from the USA Department of Defence (Post-doc Fellowship), NHMRC (Project grant) and QUT (ECR grant). In total, he has attracted >$2m in research funding towards imaging infrastructure and research projects. Dr Tse has 20 publications, in journals that include Theranostics, Oncogene, European Journal of Nuclear Medicine and Molecular Imaging Research, and Annals of Oncology.  

He has been running the TRI Preclinical Imaging Facility since late 2015, where he employs photoacoustics, high-frequency ultrasound, microCT, microPET-CT and optical imaging procedures to study in vivo models of disease.

Dr Tse also holds visiting scientist appointments with QUT and UQ.


20. Wang H, Burke LJ, Patel J, Tse BW-C, Bridle KR, Cogger VC, Li X, Liu X, Yang H, Crawford DHG, Roberts MS, Gao W, Liang X. Imaging-based vascular-related biomarkers for early detection of acetaminophen-induced liver injury. Theranostics. 2020. doi:10.7150/thno.44900

19. Yeh MC, Tse BWC, Fletcher NL, Houston ZH, Lund M, Volpert M, Stewart C, Sokolowski KA, Jeet V, Thurecht KJ, Campbell DH, Walsh BJ, Nelson CC, Russell PJ. Targeted beta therapy of human prostate cancer in vivo with Lu-177 labelled Miltuximab® antibody against glypican-1 (GPC-1). European Journal of Nuclear Medicine and Molecular Imaging Research 2020. 10, 46 doi: 10.1186/s13550-020-00637-x .

18. Siegers JY, Novakovic B, Hulme KD, Marshall R, Bloxham CJ, Thomas WG, Reichelt ME, Leijten L, van Run  P, Knox K, Sokolowski KA, Tse BW-C, Chew KY,  Christ AN, Howe G, Bruxner TJC, Karolyi M, Pawelka E, Koch RM,  Bellman-Weiler RM, Burkert F, Weiss G, Samanta RJ, Openshaw PJM, Bielefeldt-Ohmann H, van Riel D, and Short KR. A high fat diet increases influenza-A virus-associated cardiovascular damage. The Journal of Infectious Diseases. 2020. doi:10.1093/infdis/jiaa159

17. Kryza T, Khan T, Puttick S , Li C , Sokolowski KA, Tse BW-C, Cuda T, Lyons N, Gough M, Yin J, Parkin A, Deryugina EI, Quigley JP, Law RHP, Whisstock JC, Riddell AD, Barbour AP, Wyld DK, Thomas PA, Rose S, Snell CE, Pajic M, He Y, Hooper JD. Effective targeting of intact and proteolysed CDCP1 for imaging and treatment of 1 pancreatic ductal adenocarcinoma. Theranostics. 2020; 10(9):4116-4133; doi:10.7150/thno.43589.

16. Harrington BS, He Y, Khan T, Puttick S, Conroy PJ, Kryza T, Cuda T, Sokolowski KA, Tse BW-C, Robbins KK, Arachchige BJ, Stehbens SJ, Pollock PM, Reed S, Weroha SJ, Haluska P, Salomon C, Lourie R, Perrin LC, Law RH, Whistock JC, Hooper JD. Anti-CDCP1 immuno-conjugates for detection and inhibition of ovarian cancer. Theranostics. 2020 10(5):2095-2114 doi:10.7150/thno.30736

15. Chaudhary Z, Khan GM, Abeer MM, Pujara N, Tse BW-C, McGuckin MA, Popat M, Kumeria T. Efficient photoacoustic imaging using ICG loaded functionalized mesoporous silica nanoparticles. Biomaterials Science, 2019.7, 5002-5015

14. Huang X, Ali T, Nano T, Blick T, Tse BW-C, Sokolowski K, Tourell MC, Lloyd T, Thompson EW, Momot KI, Hugo HJ. Quantification of breast tissue density: Correlation between single-sided portable NMR and micro-CT measurements. Magnetic Resonance Imaging. 2019: 62:110-120

13. Wang H, Li X, Tse BW-C, Yang H, Thorling CA, Liu Y, Touraud M, Chouane JB, Liu X, Roberts MS, Liang X. Indocyanine green-incorporating nanoparticles for cancer theranostics. Theranostics 2018; 8(5):1227-1242.

12. Tse BW-C*, Volpert M*, Ratther E*, Stylianou N, Nouri M, McGowan K, Lehman ML, McPherson SJ, Roshan-Moniri M, Butler M, Caradec J, Gregory-Evans CY, McGovern J, Das R, Takhar M, Erho N, Alshalafa M, Davicioni E, Schaeffer EM, Jenkins RB, Ross AE, Karnes RJ, Den RB, Fazli L, Gregory PA, Gleave ME, Williams ED, Rennie PS, Buttyan R, Gunter JH, Selth LA, Russell PJ, Nelson CC & Hollier BG. Neuropilin-1 is up-regulated in the adaptive response of prostate tumors to androgen targeted therapies and is prognostic of metastastic progression and patient mortality. Oncogene. 2017. doi: 10.1038/onc.2016.482. * Equal first.

11. Rhee H, Ng KL, Tse BW-C, Yeh MC, Russell PJ, Nelson CC, Samaratunga H, Thomas, T, Vela I, Gobe G, Wood S. Using Prostate Specific Membrane Antigen (PSMA) Expression In Clear Cell Renal Cell Carcinoma For Imaging Advanced Disease. Pathology. 2016. doi: 10.1016/j.pathol.2016.05.011

10. Fuchs AV*, Tse BW-C*, Pearce AK, Yeh MC, Fletcher N, Huang SS, Heston WD, Whittaker AK, Russell PJ, Thurecht K. Evaluation of polymeric nanomedicines targeted to PSMA: Effect of ligand on targeting efficiency.Biomacromolecules. 2015: 16 (10), pp 3235–3247  doi10.1021/acs.biomac.5b00913. *Equal first.

9.  Russell PJ, Russell P, Rudduck C, Tse BW-C, Williams ED. Raghavan D. Establishing prostate cancer patient derived xenografts: lessons learned from older studies. The Prostate. 2015. doi: 10.1002/pros.22946

8. Tse BW-C, Cowin G, Soekmadji C, Jovanovic L, Vasireddy RS, Ling M-T, Khatri A, Liu TQ, Thierry B, Russell PJ. PSMA-targeting iron oxide magnetic nanoparticles enhance MRI of preclinical prostate cancer. Nanomedicine. 2014. doi: 10.2217/NNM.14.122.

7. Pearce AK, Rolfe B, Russell PJ, Tse BW-C, Whittaker AK, Fuchs AV, Thurecht KJ. Development of a polymer theranostic for prostate cancer. Polymer Chemistry. 2014doi:10.1039/C4PY00999A.

6. Tse BW-C, Jovanovic L, Nelson CC, de Souza P, Power CA, Russell PJ. From bench to bedside: immunotherapy for prostate cancer. Biomed Research International 2014. Article ID 981434, 11 pages. doi:10.1155/2014/981434.

5. Jacob F, Anugraham M, Alam S, Tse BW-C, Pochechueva T, Guertler R, Bovin NV, Fedier A, Hacker NF, Huflejt MF, Packer N, Heinzelmann-Schwarz V. The Glycosphingolipid P1 Is an Ovarian Cancer-Associated Carbohydrate Antigen Involved in Migration. British Journal of Cancer. 2014. doi: 10.1038/bjc.2014.455

4. Tse BW-C, Collins A, Oehler MK, Collins A, Zipplelius A, Heinzelmann-Schwarz V. Antibody-based immunotherapy for ovarian cancer – where are we at? Annals of Oncology. 2013. doi:10.1093/annonc/mdt405

3. Buehler M, Tse BW-C, Leboucq A, Jacob F, Caduff R, Fink D, Goldstein D, Heinzelmann-Schwarz V. Meta-analysis of microarray data identifies GAS6 as an independent predictor of poor survival in ovarian cancer, BioMed Research International, 2013, Article ID 238284, 9 pages, 2013. doi:10.1155/2013/238284

2. Tse BW-C, Scott KF, Russell PJ. Paradoxical Roles of Tumour Necrosis Factor-Alpha in Prostate Cancer Biology.Prostate Cancer. 2012; Article ID 128965, 8 pages. doi:10.1155/2012/128965

1. Tse BW-C, Russell PJ, Lochner M, Forster I, Power CA.  IL-18 Inhibits Growth of Murine Orthotopic Prostate Carcinomas via Both Adaptive and Innate Immune Mechanisms. PLoS ONE  2011; 6(9):e24241. doi:10.1371/journal.pone.0024241

Grants and Funding

2016 - present: Multiple infrastructure grants (eg TRI) totaling >$1m. 2016 - 2018: NHMRC Project Grant (CIC) - $561k. 2015: QUT IHBI ECR grant: $10k. 2014 - 2016: USA Department of Defence (DOD) Fellowship: $125k (USD)

Research fields

Preclinical Imaging, Oncology, Immunology, Nanotechnology


ResearcherIDORCIDGoogle Scholar